Johnson & Johnson Just Took $7 Billion in Charges and Still Raised Its Outlook. Here's What That Tells Investors.

JNJ raised its full-year guidance in Q3 2026 despite booking $7 billion in charges, a combination that signals management confidence in core earnings power even as GAAP results cratered.

The charges tell the story. A $5.5 billion talc litigation settlement made up the bulk, with the remainder tied to strategic investments in acquisitions and partnerships. The hit drove a 96% decline in GAAP earnings per share, a headline number that looks alarming in isolation.

Underneath, the operating picture held up. JNJ reported nearly 6% revenue growth in the quarter, and management still lifted its full-year outlook. Interpretation: raising guidance in the same quarter as a charge of this size suggests leadership views the settlement and deal spending as discrete, non-recurring items rather than a drag on the underlying business.

The company also reinforced its Dividend King status, with 64 consecutive years of dividend increases. For income-focused holders, the streak remains intact through a quarter that would rattle a weaker balance sheet.